Drug Safety Board Will Lead To More Advisory Cmte. Meetings – FDA’s Galson
Executive Summary
The advent of FDA's Drug Safety Oversight Board will likely lead to an increase in the number of advisory committee meetings, Center for Drug Evaluation & Research Acting Director Steven Galson said at a meeting of FDA's Science Board April 15
You may also be interested in...
FDA Safety Act Calls For “Expedited Procedures” For Drug Withdrawals
Postmarketing safety legislation proposed by Senate Finance Committee Chairman Charles Grassley (R-Iowa) and Sen. Chris Dodd (D-Conn.) calls for FDA to establish "expedited procedures" for drug withdrawals
FDA Safety Act Calls For “Expedited Procedures” For Drug Withdrawals
Postmarketing safety legislation proposed by Senate Finance Committee Chairman Charles Grassley (R-Iowa) and Sen. Chris Dodd (D-Conn.) calls for FDA to establish "expedited procedures" for drug withdrawals
Natrecor Labeling Revised To Include Expanded Mortality Analysis
Johnson & Johnson/Scios' Natrecor (nesiritide) labeling has been revised to include an expanded analysis of the mortality rates seen in pivotal trials of the congestive heart failure agent